As of Jul 21
| -0.72 / -1.51%|
The 13 analysts offering 12-month price forecasts for Neurocrine Biosciences Inc have a median target of 66.00, with a high estimate of 130.00 and a low estimate of 57.00. The median estimate represents a +40.22% increase from the last price of 47.07.
The current consensus among 14 polled investment analysts is to Buy stock in Neurocrine Biosciences Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.